Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Ticagrelor Fails Noninferiority to Prasugrel in TUXEDO-2
Added: 1 month ago Source:  Radcliffe CVRM
Written by Mirjam Boros, Radcliffe CardiologyThe optimal dual antiplatelet therapy (DAPT) following percutaneous coronary intervention (PCI) in high-risk patients with diabetes and multivessel disease remains a key clinical question. The TUXEDO-2 trial aimed to address this by directly comparing the efficacy and safety of ticagrelor versus prasugrel in this specific patient population… View more

Anticoagulation

Cardiovascular Kidney Metabolic
AHA 25: TUXEDO-2: Ticagrelor vs Prasugrel in Diabetic PCI
Author(s): Sripal Bangalore , Harriette Van Spall Added: 5 months ago
AHA Scientific Sessions 2025 — Late-breaker host Dr Harriette Van Spall (McMaster University, CA) was joined by the TUXEDO-2 Principal Investigator, Dr Sripal Bangalore to present the findings of this late-breaking randomized trial comparing ticagrelor versus prasugrel in patients with diabetes mellitus and multivessel coronary artery disease undergoing percutaneous coronary intervention (PCI)… View more

Anticoagulation

Intervention
Lifestyle Modification after PCI
Author(s): Nicholas Nguyen , Katherine C Michelis Added: 1 year ago

Prevention & Chronic Conditions